“…With increasing interest in the new antitumor targets G4 and telomerase, a number of ruthenium(II/III)-based anticancer agents targeting G4 and telomerase such as [Ru(bpy) 2 (tip)] 2+ and [Ru(phen) 2 (tip)] 2+ , [(C 6 H 6 )Ru( o -ClPIP)Cl]Cl, [Ru(bpy)(biim)], [Ru(phen)(biim)], and [Ru( p -mopip)(biim)], [Ru(bpy)(pedppz)] and [Ru(bpy)(pemitatp)], [Ru(bpy) 2 (ptpn)] 2+ and [Ru(pehn) 2 (ptpn)] 2+ , [(η 6 -arene)Ru(en)Cl] + , [Ru(ip) 3 ](ClO 4 ) 2 and [Ru(pip) 3 ](ClO 4 ) 2 , and [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ , have been reported. However, only a few chiral anticancer ruthenium complexes, such as ruthenium(II) arene PTS (RAPTA) complexes, Λ-[Ru(phen) 2 ( p -MOPIP)] 2+ and Δ-[Ru(phen) 2 ( p -MOPIP)] 2+ , [{Ru(phen) 2 } 2 tpphz] 4+ , Λ-[Ru(phen) 2 ( p -HPIP)] 2+ , and Δ-[Ru(phen) 2 ( p -HPIP)] 2+ , which display inhibitory effects on telomerase activity by stabilization of G4-DNA, have been developed.…”